DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma

Information source: Heidelberg University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Soft Tissue Sarcoma

Intervention: Sunitinib (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Heidelberg University

Official(s) and/or principal investigator(s):
Peter Hohenberger, MD PhD, Principal Investigator, Affiliation: Heidelberg University


To evaluate the toxicity of sunitinib concurrently given with irradiation for preoperative treatment of locally advanced or recurrent soft tissue sarcoma.

Clinical Details

Official title: Phase 1 Trial of Concurrent Sunitinib and Radiation Therapy as Preoperative Treatment for Locally Advanced or Recurrent Soft Tissue Sarcoma.

Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To evaluate the dose limiting toxicity and maximal tolerated dose of sunitinib given concurrently with irradiation as neoadjuvant treatment in soft tissue sarcoma.

Secondary outcome: To evaluate the response to sunitinib given concurrently with radiation as neoadjuvant treatment in soft tissue sarcoma.

Detailed description: Although the introduction of multimodal treatment of soft tissue sarcoma resulted in great progress in STS treatment, local failure still occurs in 10-20% of STS patients. Therefore further improvement of local and systemic treatment is needed in order to achieve tumor control and limb salvage. The proposed study treatment will combine external beam radiation and orally administered sunitinib. Sunitinib is a multiple receptor tyrosine kinase (RTK) inhibitor with anti-angiogenic and anti-tumoral properties. For their key role in tumor development, RTKs are regarded as excellent targets for cancer chemotherapy. External beam radiation is widely used as neoadjuvant treatment for locally advanced soft tissue sarcoma. The concurrent application of anti-angiogenic sunitinib appears reasonable, since STS are highly vascularized tumors and overexpression of VEGFR and other RTKs has been shown for various histologic soft tissue sarcoma subtypes. At first sight, the combination of antiangiogenic treatment and radiation seems to be contradictory, since anti-angiogenic treatment attacks tumor vasculature and radiation effects are decreased by hypoxia. Yet, in animal studies the concurrent application of radiation with tyrosine kinase inhibitors such as sunitinib or other antiangiogenic agents resulted in additive, if not synergistic antitumoral effects. These results can be explained by the superiority of the anti-tumoral activity of antiangiogenic agents over their hypoxia related, radiation weakening effects; or by the hypothesis of vascular normalization. It is well known that tumor vasculature is immature and ineffective in means of blood supply and oxygenation. In preclinical models, antiangiogenic agents balanced pro- and anti-angiogenic effectors which may result in maturation of tumor vasculature with improvement of blood flow and oxygen supply. The combination of sunitinib as an anti-angiogenic and anti-proliferative agent thus might not only add the therapeutic effects of the RTK-inhibitor and external beam radiation but might additionally lead to a radiosensitizing effect due to tumor vessel normalization. The Purpose of this study is to assess the toxicity of the combined treatment and to gather preliminary data on treatment efficacy.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- histologically proven soft tissue sarcoma of any histology but GIST, Angiosarcoma,

dermatofibrosarcoma protuberans, Ewing Sarcoma or Embryonal Rhabdomyosarcoma

- patients with primary tumors OR with local recurrences who did not receive prior

radiation therapy OR with solitary metastatic lesions may be included

- complete resection after neoadjuvant treatment is expected

- age of 18 or older

- ECOG performance score 0 or 1

- normal organ and bone marrow function

- ability to give written informed consent

Exclusion Criteria:

- medication with inhibitors or inducers of CYP3A4

- prior therapy with tyrosine kinase inhibitors or conventional chemotherapy within 4

weeks before study inclusion

- history of myocardial infarction, stroke or thromboembolic events

- clinical signs of heart failure (NYHA 3 or 4)

- anticoagulation with Vitamin K antagonists

- acquired or hereditary coagulopathy

- uncontrolled hypertension

- uncontrolled intercurrent illness

- women who are pregnant or breastfeeding

Locations and Contacts

Helios Klinikum Bad Saarow, Bad Saarow 15526, Germany

University Medical Center Mannheim, Mannheim 68167, Germany

Additional Information

Starting date: February 2012
Last updated: May 27, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017